Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial

NCT04432142 is registered in ClinicalTrials.gov with Maastricht Radiation Oncology as lead sponsor.

NCT NCT04432142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04432142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial
Lead sponsor
Maastricht Radiation Oncology
Phase
Observational
Overall status
Active, not recruiting
Start date
April 1, 2021
Completion date
December 1, 2026
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung